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Abstract
Background: In Kawasaki disease (KD), a vasculitis of unknown etiology, the most serious complication is the
development of coronary artery aneurysm (CAA). To date, the exact pathomechanism of KD is unknown. Both
environmental and genetic factors seem to be associated with the development of the disease.
Methods: Data on KD patients recruited from the population-based German Pediatric Surveillance Study during
2012–2014 were used to evaluate the impact of various factors from the perinatal and infancy period on the
development of KD. The study design was a matched case-control study with respect to age, sex and place of
residence (n = 308 KD cases, n = 326 controls). All KD patients were individually re-evaluated; all fulfilled the
international diagnostic KD criteria. A standardized questionnaire was used to review breastfeeding practices,
vitamin D supplementation and birth characteristics. Logistic regression analyses were performed to obtain odds
ratios (OR) for various risk factors among the case-control pairs. Simple measures of association were used to assess
the impact of these factors on the clinical course.
Results: There was no difference in lengths of gestation, birth weight or parturition between KD patients and
controls, but independently from each other vitamin D supplementation and breastfeeding were negatively
associated with KD, even when adjusted for age, place of residence and sex. The duration of vitamin D was
significantly shorter among children with KD than among children without KD (p = 0.039, OR = 0.964, 95% CI: 0.931–
0.998), as was the duration of breastfeeding (p = 0.013, OR = 0.471, 95% CI: 0.260–0.853). Comparing KD patients
with and without breastfeeding and/or vitamin D supplementation, there were no differences regarding
developing CAA, being refractory to intravenous immunoglobulin treatment, age at onset of the disease and levels
of inflammatory laboratory values.
Conclusion: Our findings indicate breastfeeding and vitamin D supplementation to have protective effects in
association with KD in our study population; however, these seem not to influence the natural course of the
disease. Although the overall effects were relatively small, they nevertheless underline the overall benefit of both
interventions.
Trial registration: Clinical Trial Registration: German clinical trial registration, http://apps.who.int/trialsearch/Trial2.
aspx?TrialID=DRKS00010071. Date of registration was 26. February 2016. The trial was registered retrospectively.
Keywords: Kawasaki disease, Coronary artery aneurysm, Risk factors, Vitamin D supplementation, Breast feeding
* Correspondence: karomeyer@hotmail.com
1Department of Congenital Heart Disease and Pediatric Cardiology,
University Heart Center Freiburg, Mathildenstraße 1, D-79106 Freiburg,
Germany
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Meyer et al. BMC Pediatrics           (2019) 19:66 
https://doi.org/10.1186/s12887-019-1438-2
Background
Kawasaki disease (KD) is a vasculitis of unknown eti-
ology, which can be complicated by the development of
coronary artery aneurysm (CAA). It is a rare disease, pri-
marily affecting children under five years of age. The in-
cidence among Asian children is much higher than
among Caucasians. In our 2011–2012 cohort, we esti-
mated an incidence of 7.2/100,000 in Germany (children
< 5 years) [1, 2]. By contrast, for the year 2012 Japan re-
ported the highest incidence worldwide, with 265/
100,000 children (aged 0–4 years) diagnosed [3]. Cause
and pathogenesis of KD are unclear. A combination of
different risk factors, for disease development, along
with a genetic predisposition, so far has been assumed
[2, 4, 5]. To further investigate this assumption, we ana-
lysed the impact of different risk factors for KD during
the perinatal period and infancy. Week of gestation,
birth weight and type of parturition are known to impact
health in later life [6]. Caesarean delivery, for example, is
known to be a risk factor for multiple chronic immune
diseases, including asthma and juvenile idiopathic arth-
ritis [7]. Similarly, vitamin D supplementation and
breastfeeding are well-known for their health benefits: In
Germany, vitamin D supplementation generally is rec-
ommended for the first year of life. Besides playing an
important role in the bone and calcium balance [8], vita-
min D also regulates other cell functions and supports
the immune system overall [9]. Furthermore, epidemio-
logical studies on vitamin D deficiency show potential
associations with cardiovascular diseases [10] and vascu-
litis [11].
For its health and other benefits, breastfeeding is pref-
erable to formula feeding. Among other advantages,
breastfeeding seems to protect against a variety of infec-
tious diseases [12] and non-breastfed children have a
higher risk of developing allergies and bronchial asthma
later in life [13]. A Japanese study already has indicated
a potential protective effect in KD [14].
During the perinatal and infancy periods, these and
other factors potentially play a role in the pathogenesis
of KD. Therefore, in a population-based, retrospective
case-control study we investigated the association and
impact of birth characteristics, breastfeeding practices
and vitamin D supplementation on KD.
Methods
Our study was designed as an epidemiological
case-control study. KD cases were recruited from the
population-based German Pediatric Surveillance Study
(ESPED) from January 2012 to December 2014 [15]. For
the ESPED report, pseudonymous identifiers were used.
A standardized questionnaire was sent to reporting phy-
sicians requesting clinical and laboratory details from
each KD case. Additionally, we requested that reporting
physicians ask parents (via written informed consent) to
agree to disclosure of their child’s identity so that our
group could conduct follow-up questioning. In cases
where such consent was provided, it became possible for
us to validate the original ESPED data via discharge let-
ters, recorded laboratory values and echocardiographic
findings. For details see Additional file 1.
Due to data protection regulations, we only were able
to include those KD cases where parents had provided
written informed consent. Data regarding breastfeeding
practices, vitamin D supplementation and birth charac-
teristics were collected via a standardized questionnaire,
and responses were provided online and in telephone in-
terviews (see Additional file 2).
In order to obtain control cases from the KD patient’s
own immediate environment, control cases (n = 326)
were recruited from among the personal contacts of the
KD case. First, the parents of KD cases were asked
whether they might be able to recruit one of their child’s
friends to take part in the survey. If no immediate friend
of the KD cases was available or interested, then the
treating paediatrician was asked to find a child who met
the following criteria: (1) same sex, (2) same place of
residence (≤ 50 km distance), (3) same age (≤ 6months
age difference) and (4) no medical history of KD. Once
KD and control cases had been established, data were
collected in an anonymous way through an online ques-
tionnaire. Case-control-pairing was conducted by using
the ESPED pseudonymous identifier. In some cases,
more than one control case was able to be recruited. For
these KD cases, the control case was selected manually
accordingly to best fit, which was based upon: (1) age,
(2) gender and (3) place of residence. The best fitting
case-control-pair was used for the statistical analysis.
All ESPED-reported KD cases (n = 631) were
re-evaluated and checked for fulfilling the American
Heart Association (AHA) guidelines for classification as
either complete or incomplete KD cases [16]: Complete
cases were defined as those with persistent fever for ≥5
days or fever that resolved within five days in response
to intravenous immunoglobulin (IVIG) treatment. In
addition, display of at least four principal clinical fea-
tures was required: (1) changes in extremities; (2) poly-
morphous exanthema; (3) bilateral conjunctival injection
without exudate; (4) enanthema of lips and oral cavity;
and (5) bilateral cervical lymphadenopathy. By contrast,
incomplete cases included either (A), (B) or (C) as out-
lined below:
(A)Those with fever (independent of age), plus fewer
than four clinical features, plus detection of CAA.
Diagnosis of CAA was based upon the clinical
judgment of the reporting physician. In Germany,
two criteria for CAA are applied: The first criterion
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used is from the Japanese Ministry of Health, which
defines aneurysms either as a lumen > 3mm in
children under 5 years old, or as a diameter 1.5
times the size of the surrounding segment, or else
as a clearly irregular lumen. The second criterion
applied is a Z-score of above 2.5 for one of the cor-
onary arteries.
(B) Those with fever under 6 months of age who have
fewer than four clinical features.
(C) Those with fever over 6 months of age, plus three
clinical features, plus laboratory evidence of
systemic inflammation (CRP ≥30 mg/dl or ESR ≥40
mm/h) in combination with at least three of the
following other abnormal supplemental laboratory
findings: (1) increased alanine transaminase, (2)
albumin ≤3.0 g/dL, (3) leukocyturia, (4) anaemia for
age, (5) leukocytosis (≥15,000/mm3) and (6)
thrombocytosis (≥450,000/mm3) [16].
In accordance with AHA guidelines, in cases where
fever persists for over 36 h, German recommendations
stipulate the administration of a second IVIG therapy
course. Our study defined such cases as refractory to
IVIG.
Out of a total of n = 631 reported KD cases, n = 69
cases did not fulfil the AHA case definitions. Follow-up
with complete data in response to our questionnaire was
available in n = 308 cases. For details see Fig 1.
Statistics
First, we analysed the quality of our matching (depend-
ing on the factors: age, place of residence and sex).
Cross-tables, measures of association (phi coefficient,
contingency coefficient, Cramer’s V and Pearson correl-
ation coefficient) and OR were used. To identify possible
risk factors for KD, we performed univariate analyses.
For the main analysis, we employed a logistic regression
conditional on the case-control pairs. As a sensitivity
analysis, we also applied an unconditional logistic regres-
sion adjusting for the matching factors. The latter ap-
proach uses all available observations without restriction
on successfully matched cases and controls; this results
in a higher statistical power but can introduce some bias
[17]. Therefore, the results of the conditional logistic re-
gression were taken to represent our main results, while
the results of the unconditional logistical regression were
used as a sensitivity analysis to verify the main results.
All potential risk factors were analysed for associations
with clinical findings (developing CAA, level of inflam-
matory laboratory values, age at onset of disease and be-
ing refractory to IVIG treatment). For this, we used the
Chi-squared test, Spearman’s rank correlation coefficient
and Cramer’s V. For breastfeeding and vitamin D supple-
mentation, the age at onset of disease was examined
using the Mann-Whitney test. Statistical analyses were
performed using the statistical software R (3.3.2) and
SPSS (24.0.0.0, IBM).
Matching
A case-control matching was made based on sex, age
and place of residence (Figs. 2, 3 and Table 1). The mea-
sures of association, i.e. contingency coefficient and Cra-
mer’s V were > 0.9 for age and place of residence. This
attests to the high quality of the matching and further-
more shows that the results would have been distorted,
had the matching been ignored. With regard to sex, the
measures of association were between 0.577 and 0.706,
indicating a satisfactory case-control matching. Here, the
OR for the matching factor sex was 36,346, meaning that
the likelihood that a KD and control case would have
Fig. 1 Study population. *2012≤ 4 years of age: n = 189, 2013/
2014≤ 17 years of age: n = 442
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the same sex was 36 times higher than that of their hav-
ing different sexes.
Results
Our study cohort was composed of n = 308 KD cases
and n = 326 controls (Fig. 1). The median age of KD
cases during the acute phase of the disease was 30
months. On the day that the data collection was com-
pleted (March 22, 2017), the median age of KD cases
was 6.5 years, and 63% were male. Control cases had a
median age of 6.3 years on the day of the data collection,
and 58% were male (Table 2). KD and control cases were
reported from all regions of Germany (Fig. 3). Ethnic
background was available from 95.1% of KD cases (n =
293) and showed a breakdown of 97.6% Caucasian (n =
286), 1.7% Asian (n = 5) and 0.7% black African (n = 2).
Perinatal risk factors compared in KD cases vs. control
cases
The dataset matching was prepared for optimal com-
parison. Thus, only complete case-control pairs (max-
imum n = 227) were used for the conditional logistic
regression. When information was missing for one risk
factor, the case-control pair was excluded from these
analyses. As a sensitivity analysis, we also applied the
unconditional logistic regression (maximum n = 542). In
cases where the results differed from those of the condi-
tional logistic regression, we discussed the discrepancy.
For simple description, the entire data set (n = 308 KD
cases and n = 326 control cases) was taken into
consideration.
Among the perinatal factors, there were no significant
differences between KD and control cases regarding
week of gestation, birth weight and parturition (Table 3).
However, breastfeeding and vitamin D supplementation
did show a protective effect for KD (Table 3). The OR
for breastfeeding for longer than two weeks was 0.471
[95% CI 0.260–0.853] as compared to breastfeeding for
less than two weeks.
The evaluation of vitamin D supplementation also re-
vealed small but significant differences between the KD
group and the control group. Our analysis showed that
KD cases received Vitamin D for significantly shorter
time periods than did the controls (Mean cases = 5
months versus Mean controls = 6 months, OR 0.96, 95%
CI 0.931–0.998, p = 0.039, see Table 3).
To estimate a possible confounding, the association
between breastfeeding and vitamin D supplementation
was tested. The measurements of association showed no
obvious associations between vitamin D supplementa-
tion and breastfeeding: Spearman-Rang-Correlation (rs =
− 0.039), Eta-Squared (η2 = 0.000) and Cramer’s V (V =
0.141).
Influence of risk factors on the clinical course
We tested whether the duration of breastfeeding and of
vitamin D supplementation influenced the clinical
course of KD cases. The clinical variables CAA, being
refractory to IVIG treatment, and the level of inflamma-
tory serum markers were analysed to compare KD cases
with shorter vs. longer breastfeeding periods and/or lon-
ger vs. shorter vitamin D supplementation. Comparing
KD cases with CAA (in the acute phase) to KD cases
without detection of CAA did not show significant dif-
ferences with respect to the duration of breastfeeding
and vitamin D supplementation. Similarly, KD cases
Fig. 2 Scatterplot - Matching KD and control cases by age at the onset of fever in KD cases. One dot meets a matched pair. Dots that are below
the red line were excluded. It is noticeable that most dots are on or next to the diagonal. Consequently, a successful matching based on age can
be assumed
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being refractory to IVIG did not differ from IVIG re-
sponders (Table 4). Also, the impact on systemic inflam-
matory serum markers (CRP, leukocytes and platelets)
did not demonstrate any significant difference (Table 4).
In addition, we investigated whether breastfeeding and
vitamin D supplementation might influence disease
onset, since not-breastfed/not-supplemented cases po-
tentially might develop KD earlier than breastfed/supple-
mented cases (Table 5). However, the median age in the
two categories (< 2 weeks vs. > 2 weeks of breastfeeding,
along with regular vs. irregular supplementation of vita-
min D) was not significantly different (p-value 0.802 and
0.534, respectively). For the duration of vitamin D sup-
plementation, the correlation coefficient was small and
negative. The coefficient of the linear model showed no
significant relation to disease onset (Table 5).
Discussion
Our study is the first of a nationwide, population-based
cohort in Germany. The study investigates various peri-
natal and infancy factors in association with Kawasaki
disease and its disease course. Our data reinforce the
findings of a large study from Japan which has indicated
Fig. 3 Matching: Geographical distribution of KD patients and their controls within Germany. We have created a map of Germany with the
software MATLAB. Shapefiles, a file format containing geodata from the Database of Global Administrative Areas were used to extract the
administrative boundaries in Germany. The individual postcodes were assigned to the respective federal state
Table 1 Measures of association for the matching factors sex,
age and place of residence
Matching factors
Sex Age Place of residence
Measures of association
Phi coefficient 0.706
Contingency coefficient 0.577 0.945 0.945
Cramer’s V 0.706 0.961 0.961
Pearson correlation coefficient 0.901
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that breastfeeding may be protective for KD [14]. Vita-
min D supplementation appears to have a minor pro-
tective effect for KD as well. However, an influence of
these factors on the clinical course (development of
CAA, raised systemic inflammatory markers, being re-
fractory to IVIG treatment) was not observed. Since the
risk factors age, sex and place of residence were used as
matching factors, they could not be included in our ana-
lysis of potential risk factors.
Our data regarding vitamin D supplementation
showed that KD cases in our cohort received signifi-
cantly less vitamin D than their healthy controls. In a re-
cently published study that measured vitamin D levels
during the acute phase of KD, levels proved to be signifi-
cantly lower compared to controls [18]. Stagi et al. also
have described a reduced serum vitamin D concentra-
tion in KD cases. These authors suggested that vitamin
D may be reduced by the inflammatory process [19].
Our findings indicate that lower vitamin D levels may
already play a role before disease onset, since in our
cohort, children with KD had a shorter duration of vita-
min D supplementation. However, due to our study de-
sign, we were not able to determine the actual vitamin D
levels prior to the development of KD.
Because the skin of infants is not able to produce suffi-
cient vitamin D, without supplementation, infants will
develop vitamin D deficiency [20]. For this reason, in
countries such as the USA, infant food is supplemented
with vitamin D. In countries such as Germany, a daily
vitamin D supplementation is recommended during the
first year of life [8]. The Nutrition Commission of the
German Society for Pediatric and Adolescent Medicine
recommends 400–500 IU / day during the first year of
life [21].
The anti-inflammatory and immunomodulatory effects
of vitamin D are well-described in several studies [22].
Vitamin D appears to block factors (e.g., tumor necrosis
factor α) that are essential for the activation of proin-
flammatory cytokines [23]. This raises the possibility of
vitamin D being used as complementary therapy in
immune-mediated diseases such as KD. Some studies
already indicate that reduced vitamin D levels may nega-
tively effect the clinical course. First, reduced vitamin D
levels seem to be associated with the prevalence of car-
diovascular diseases and the development of CAA [19,
24]. Low vitamin D levels inducing endothelial dysfunc-
tion may partially explain this association [25]. Second,
Zhang et al. have described significantly reduced vitamin
D levels in KD patients who were refractory to IVIG
treatment [18]. We investigated both of these factors —
CAA development and being refractory to IVIG treat-
ment — but were not able to find a significant associ-
ation with vitamin D supplementation. Furthermore, due
to the anti-inflammatory activity of vitamin D, we also
investigated other inflammatory serum markers, includ-
ing CRP, thrombocytes and leukocytes — ones that
might indicate higher disease activity in KD cases. How-
ever, the markers did not differ between KD cases with
longer vs. shorter vitamin D supplementation. Stagi et
al. have reported on a negative association regarding low
vitamin D serum levels with CRP titers [19]. Addition-
ally, Jun et al. retrospectively reviewed whether low vita-
min D levels were associated with resistance to IVIG
therapy in KD cases. They found vitamin D deficiency to
be associated with IVIG resistance, but not associated
with inflammatory markers [26]. In summary, we con-
clude that vitamin D could potentially play a role in the
inflammatory process of KD. However, for a better un-
derstanding of its mechanism, additional prospective
studies would be necessary.
The perinatal factor of breastfeeding showed a signifi-
cant protective effect. In general, breastfeeding is recom-
mended for at least six months due to its various health
benefits [27]. Breast milk contains lactoferrin and
Table 2 Clinical details of KD vs. control cases
KD cases Control cases
(n = 308) (n = 326)
Age in yearsa
Median 6.5 6.3
Sex, n (%)
Female 114 (37) 137 (42)
Male 194 (63) 189 (58)
KD diagnosis, n (%)
Complete 269 n.a.
Incomplete with laboratory changes b 15 n.a.
Incomplete with CAA 24 n.a.
Days until start of IVIG therapy
Average 6.6 n.a.
Min – max 0–32 n.a.
Refractory to IVIG treatment c
Yes > 1 IVIG cycle 29 (13.4%) n.a.
Therapy with steroids, n (%)
Yes, for KD treatment 53 (17.2) n.a.
Yes, for other reasons 9 (2.9) n.a.
CAA in acute phase, n (%)
Yes 36 (11.6) n.a.
CAA after one year c, n (%)
Yes 13 (5.9) n.a.
aat the end of the case-control study survey (i.e, March 22, 2017)
b according to the guidelines of the American Heart Association at least three
other abnormal supplemental laboratory findings, namely (1) increased alanine
transaminase, (2) albumin ≤3.0 g/dL, (3) leukocyturia, (4) anaemia for age, (5)
leukocytosis (≥15,000/mm3) (6) thrombocytosis (≥450,000/mm3) [16]
cfor cases reported in 2013/2014 n = 217; CAA = coronary artery aneurysma;
n.a. = not applicable
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lysozyme, which non-specifically inhibit all types of
pathogenic microorganism [28]. In addition, secretory
immunoglobulin A confers specific protection against
mucosal pathogens [29, 30]. Breastfeeding rarely has
been considered in association with KD. Data from a re-
cent study in Japan showed that children who were
breastfed were less likely to develop KD [14]. The Japa-
nese authors described a protective effect for both exclu-
sive (OR 0.26; 95% CI 0.12–0.55) and partial
breastfeeding (OR 0.27; 95% CI 0.13–0.55) as compared
to formula milk [14]. Even partially breastfed children
showed a general benefit. Therefore, the protective effect
of breast milk probably is not linked to the duration of
breastfeeding but rather to substances in either breast
milk or colostrum [14], the latter of which contains high
levels of secretory antibodies [31]. Additional investiga-
tions will be needed to identify these protective sub-
stances. In the future, infants who cannot be breastfed
might be able to receive these protective substances for
protective purposes.
In general, breastfeeding has a positive effect on the
outcome of infections in infants. For example, Nishi-
mura et al. have described shorter hospital stays and bet-
ter outcomes in breastfed children infected with
respiratory syncytial virus [32]. However, the effect of
breastfeeding on the outcome of KD remains unknown.
In our study, we were unable to find an association be-
tween the duration of breastfeeding and the appearance
of CAA, being refractory to IVIG treatment or the
amount of inflammatory serum markers. Therefore, pro-
longed breastfeeding seems not to be associated with a
milder clinical course in KD. Protection against infection
by breast milk, the so-called maternal passive immunity,
relates to the first six months of feeding [33]. We inves-
tigated the potential impact of breastfeeding and vitamin
D supplementation on the age of disease onset. However,
in shorter-breastfed and/or shorter-supplemented cases,
KD did not occur sooner than in other KD cases. It is
therefore questionable whether maternal passive im-
munity has an effect on the age of KD onset.
Table 3 Demographic characteristics of KD and control cases and potential perinatal factors for KD development (frequencies,
means and logistic regression with p-value, OR and 95% CI)
KD cases
(n = 308)
Control cases
(n = 326)
Conditional logit – model (n = 454)
Unconditional logit - model (n = 542)
OR [95% CI] p-value
Duration of pregnancy in weeks
Average (±SD) 39 (±2.057) 39 (±1.944) 0.992 [0.891–1.105]
0.965 [0.883–1.050]
0.891
0.414
Parturitiona, n (%)
Vaginal 128 (65.6) 194 (70.8) 1 (reference) 0.388
0.302
Cesarean section 67 (34.4) 80 (29.2) 1.286 [0.727–2.274]
1.259 [0.813–1.953]
Birth weight in gram
Average (±SD) 3340 (±527.052) 3383 (±537.734) 0.999 [0.999–1.000]
0.999 [0.999–1.000]
0.715
0.399
Range 1560 – 4960 1171 – 4910
Duration of breastfeeding, n (%)
< 2 weeks 66 (21.4) 30 (9.2) 1 (reference) 0.013
0.001
> 2 weeksb 242 (78.6) 296 (90.8) 0.471 [0.260–0.853]
0.415 [0.243–0.687]
Vitamin D supplementation in the first year of life, n (%)
No 64 (20.8) 53 (16.3) 1 (reference) 0.782
0.051
Yes 244 (79.2) 273 (83.7) 0.926 [0.537–1.595]
0.623 [0.383–0.995]
Duration of vitamin D supplementation in the first year of life in months
Mean (±SD) 5.16 (±5.749) 6.03 (±5.596) 0.964 [0.931–0.998]
0.965 [0.935–0.995]
0.039
0.024
Regularity of vitamin D supplementationc, n (%)
Irregular 65 (26.6) 55 (20.0) 1 (reference) 0.042
0.060
Regular 179 (73.4) 220 (80.0) 0.559 [0.319–0.980]
0.642 [0.402–1.016]
a not asked in n = 52 control cases vs. n = 113 KD cases, b includes partially breastfed children. crefers only to cases that received vitamin D
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In conclusion, breastfeeding seems to have a protective
effect on the development of KD, supporting the health
benefit of general breastfeeding recommendations.
The strength of our case-control study is based upon
the large number of KD cases in a Germany-wide co-
hort, along with the excellent comparability between our
KD and control groups. KD cases were reported from all
regions of Germany, as were the control cases who were
recruited in parallel. A possible bias by the confounder
age, sex and place of residence was able to be minimized
through a thorough matching process [34]. In addition,
all KD cases were evaluated using a standardized ques-
tionnaire and they fulfilled internationally-accepted KD
criteria [16]. These strict criteria minimized the risk of
misdiagnosed KD cases being included in our study.
However, the validity of our results should be inter-
preted in light of our retrospective study design and
considered in context of its known limitations. Although
KD cases have been reported as part of a prospective
surveillance study, data analysis for this study was based
upon a retrospective survey conducted over a period of
three years. The time period between the acute phase of
KD and that of this survey was at least one year. Data
quality strongly depends upon the memory ability of the
parents, the so-called recall bias. Therefore, we cannot
rule out the possibility that families of sick children may
have been more likely to remember potential risk factors
and/or living conditions than families in the control
group did. Another limitation relates to the fact that KD
cases were reported from a large number of hospitals,
most of whom were without a standardized treatment
protocol. KD therapy varies considerably. Some of our
KD cases received corticosteroids early in the course of
disease that might have impacted the patients’ clinical
Table 4 Influence of vitamin D supplementation and breastfeeding on the course of disease
Vitamin D supplementation
(n = 308)
Breastfeeding
(n = 308)
0–6 months 7–12months p-value
[95% CI]
< 2 weeks > 2 weeks p-value
[95% CI]
CAA, n (%)
Yes 13 (11.4) 23 (11.9) 0.905
[−0.079–0.070]
5 (7.6) 31 (12.8) 0.185
[− 0.130–0.025]
No 101 (88.6) 171 (88.1) 61 (92.4) 211 (87.2)
Refractory to IVIGa, n (%)
Yes 9 (11.5) 20 (14.5) 0.543
[−0.125–0.066]
4 (8.7) 25 (14.7) 0.233
[−0.160–0.039]
No 69 (88.5) 119 (85.5) 42 (91.3) 145 (85.3)
Laboratory, average (±SD)
CRP b 93,55
(±86.703)
105,08
(±82.948)
0,248
[−31.119–8.057]
103,04
(±84.499)
100,20
(±84.539)
0,809
[−20.255–25.942]
Thrombocytes c 235.48
(±280.350)
210.95
(±241.805)
0.421
[−35.367–84.431]
570.56
(±277.776)
577.64
(±235.789)
0.705
[−54.229–80.070]
Leukocytes d 17.44
(±7.853)
17.31
(±7.613)
0.885
[−1.667–1.931]
17.23
(±6.582)
17.39
(±7.978)
0.883
[−2.279–1.962]
a only KD patients from 2013/2014 n = 217; b in mg/dl; c in T/μl; d in T/μl
Table 5 Influence of vitamin D supplementation and breastfeeding on disease onset
Age in months a (±SD) Wilcoxon rank Spearman correlation coefficient
(n = 308 b) p-value
Regularity of vitamin D supplementation c
Irregular 34.95 (±24.329) 0.534
Regular 35.56 (±26.592)
Duration of vitamin D supplementation in the first year of life in months
0–6 39.04 (±26.90) −0.095
7–12 34.95 (±26.07)
Duration of breastfeeding d
< 2 weeks 36.14 (±23.691) 0.802
> 2 weeks c 36.51 (±27.093)
a at onset of fever, b only KD cases, c refers only to cases that got vitamin D (n = 244), d includes partially breastfed cases
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course, potentially outweighing the influence of vitamin
D supplementation and breastfeeding. Finally, a potential
confounding between different variables cannot be ruled
out. For example, a higher social status often determines
a healthier life style. By recruiting control cases via
friends and relatives of KD cases, an attempt was made
to achieve the best possible comparison regarding
socio-economic status. Due to data protection regula-
tions, we were not able to collect additional data regard-
ing the socio-economic status of both KD and control
cases.
Another limitation relates to the simultaneous screen-
ing for several risk factors. The so-called multiple testing
problem (look-elsewhere effect) describes randomly sig-
nificant findings due to the large number of factors stud-
ied [35]. For this reason, our findings should be verified
in future prospective studies of larger and more diverse
study populations.
Conclusion
In association with KD in our study population, our re-
sults indicate protective effects of vitamin D supplemen-
tation and further reinforce breastfeeding to have a
protective effect. However, these factors seem not to in-
fluence the natural course of the disease. Although the
effects were small, they nevertheless underscore the
overall benefit of both interventions.
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